Centogene (CNTG) announced the extension of an ongoing partnership with Takeda (TAK) to diagnose patients with Lysosomal Storage Disorders. Under the renewed agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNTG:
- CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
- Centogene receives Nasdaq notice of delisting, will request hearing
- CENTOGENE Explores Strategic Alternatives
- CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
- Centogene to explore a range of strategic alternatives